Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.
Video
Back to the drawing board for MPN combo
NEWPORT BEACH, CALIF. – Ruxolitinib plus decitabine won’t proceed to a phase 3 trial for the treatment of accelerated or blast phase...
Video
Creating CAR T-cell therapies for T-cell malignancies
NEWPORT BEACH, CALIF. – Dr. John F. DiPersio discusses preclinical research testing CAR T-cell therapies in T-cell malignancies.
News
SB-525 gene therapy looks viable for hemophilia A
Two of eight patients treated with the investigational gene therapy SB-525 have achieved normal factor VIII levels, according to interim study...
News
In situ vaccination produced responses in indolent NHL
In situ vaccination induced regression of tumors that were directly targeted, as well as tumors that were not treated, in a small study of...
Article
New leaders at SGO, AACR
Dr. Warner K. Huh is named president of the Society of Gynecologic Oncology, and appointments are made at AACR, NCCN, and MD Anderson.
News
Polatuzumab outperforms pinatuzumab in non-Hodgkin lymphoma
Polatuzumab vedotin plus rituximab produced more durable responses than did pinatuzumab vedotin plus rituximab in patients with relapsed or...
News
Combo could replace standard conditioning regimen for myeloma
The combination of busulfan plus melphalan produced superior progression-free survival but no overall survival advantage in the phase 3 trial.
News
Cancer researchers take home AACR honors
The researchers will be recognized at the annual meeting of the American Association for Cancer Research in Atlanta.
Article
Brachytherapy access may mediate poor cervical cancer survival in blacks
“This is the first study, to our knowledge, to show such an interaction between race and survival being mediated by one particular treatment...
News
Combo shows promise for endometrial, ovarian cancers
HONOLULU – Combination lenvatinib and paclitaxel produced an objective response rate of 65%, and most adverse events were grade 1 or 2.
News
Perceived cancer risk may improve access to HPV vaccine
HONOLULU – The perceived risk of HPV-related cancer appears to overcome variables that typically impede access to...
News
Triplet appears safe, effective for gynecologic cancers
HONOLULU – Tumor response rate was 40% with pembrolizumab plus bevacizumab and oral metronomic cyclophosphamide in patients with recurrent...
News
Combo may improve PFS, OS for certain ovarian cancer patients
HONOLULU - Combining avelumab with pegylated liposomal doxorubicin may provide a survival benefit in certain patients with platinum-resistant or...
News
Financial toxicity may be common in gynecologic cancer patients
HONOLULU – A small survey suggests financial toxicity may be common among gynecologic cancer patients starting a new line of treatment.
News
Financial assistance programs may speed treatment for cervical cancer
HONOLULU – Financial assistance programs may help lower-income cervical cancer patients complete treatment in a...